Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

DBCOND0163133Immune System DiseasesRespiratory Tract Diseases

Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) is the indication for 2 drugs in DrugBank. It is covered by 3 curated, structured indications.

Also known as
Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) · Systemic Sclerosis-associated Interstitial Lung Disease · Scleroderma-Associated Interstitial Lung Disease (SSC-ILD) · Systemic Sclerosis Associated Interstitial Lung Disease
Classified under
Indicated drugs

What you can answer from here — as of October 23, 2026

2Indicated drugsWith each drug's targets and mechanism
Listed above
3Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Drug reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In